Melissa Stanton
Mayo Clinic in Arizona(US)Mayo Clinic Hospital(US)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Cancer Genomics and Diagnostics, Bladder and Urothelial Cancer Treatments, Renal and related cancers, Epigenetics and DNA Methylation
Most-Cited Works
- → PD-L1 expression in nonclear-cell renal cell carcinoma(2014)298 cited
- → PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation(2015)190 cited
- → Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death(2015)73 cited
- → Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder(2013)67 cited
- → Urothelial Tumors of the Urinary Bladder in Young Patients: A Clinicopathologic Study of 59 Cases(2013)54 cited
- → Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response(2015)46 cited
- Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.(2010)
- → Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma(2016)40 cited
- Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma.(2010)
- → Recommendations for Tissue Microarray Construction and Quality Assurance(2019)32 cited